Stroke pharmacogenomics

Bibliography

• Abbott A. You're your genes? Take one of these, three times a day. Nature 2003;425(6960):760-2
   PubMedGoogle Scholar
• Evans WE, McLeod HL. Pharmacogenetics-drug disposition, drug target, and side effects. N Engl J Med 2003;348(6):538-49
   PubMed Web of Science ®Google Scholar
• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279(15):1200-5
   PubMedGoogle Scholar
• Phillips KA, Veenstra DL, Oren E, Potential role of pharmacogenetics in reducing adverse drug reactions: a systematic review. JAMA 2001;286(18):2270-9
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348(6):529-37
   PubMed Web of Science ®Google Scholar
• Wolfe CD. The impact of stroke. Br Med Bull 2000;56:275-86
   PubMed Web of Science ®Google Scholar
• Adams HP Jr, Woolson RF, Clarke WR, Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Control Clin Trials 1997;18(4):358-77
   PubMedGoogle Scholar
• Flossman E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 2004;35:212-27
   PubMedGoogle Scholar
• Kiely DK, Wolf PA, Cupples LA, Familial aggregation of stroke. The Framingham study. Stroke 1993;24:1366-71
   PubMed Web of Science ®Google Scholar
• Kissela BM, Sauerbeck L, Woo D, Subarachnoid hemorrhage: a preventable disease with a heritable component. Stroke 2002;33:1321-6
   PubMed Web of Science ®Google Scholar
• Brass LM, Isaacsohn JL, Merikangas KR, A study of twins and stroke. Stroke 1992;23(2):221-3
   PubMedGoogle Scholar
• Wannamethee SG, Shaper AG, Ebrahim S. History of parental death from stroke or heart trouble and the risk of stroke in the middle-aged men. Stroke 1996;27:1492-8
   PubMedGoogle Scholar
• Ayala C, Greenlund KJ, Croft JB, Racial/ethnic disparities in mortality by stroke subtype in the United States, 1995-1998. Am J Epidemiol 2001;154:1057-63
   PubMed Web of Science ®Google Scholar
• Hademos GJ, Alberts MJ, Awad I, Advances in the genetics of cerebrovascular disease and stroke. Neurology 2001;56:997-1008
   PubMedGoogle Scholar
• Natowicz M, Kelley RT. Mendelian etiologies of stroke. Ann Neurol 1987;22:175-92
   PubMedGoogle Scholar
• Ruchoux MM, Brulin P, Brillault J, Lessons from CADASIL. Ann NY Acad Sci 2002;977:224-31
   PubMedGoogle Scholar
• Ridker PM, Hennekens CH, Lindpaintner K, Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-17
   PubMed Web of Science ®Google Scholar
• Tatlisumak T, Syrjala M, Lndsberg P, FV-ARG-506-GLN-mutation-associated resistance to activated protein C in ischemic stroke. J Stroke Cerebrovasc Dis 1995;5:192-6
   PubMedGoogle Scholar
• Rosendaal FR, Siscovick DS, Schwartz SM, A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997;90:1747-50
   PubMed Web of Science ®Google Scholar
• Longstreth WT, Rosendaal FR, Siscovick DS, Risk of stroke in young women and two prothrombiti mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke 1998;29:577-80
   PubMed Web of Science ®Google Scholar
• Press RD, Liu XY, Beamer N, Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. Stroke 1996;27:44-8
   PubMedGoogle Scholar
• Vandeubrouke JP, Koster T, Brit E, Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutations. Lancet 1994;344:1453-7
   PubMedGoogle Scholar
• Perry IJ, Refsum H, Morris RW, Prospective study of serum total homocysteine concentrations and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8
   PubMed Web of Science ®Google Scholar
• Markus HS, Ali N, Swaminathan R, A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke 1997;28:1739-43
   PubMed Web of Science ®Google Scholar
• Carlsson LE, Greinacher A, Spitzer C, Polymorphisms of the human platelet antigens HPA-1,-HPA-2, HPA-3, and HPA-5 on the platelet receptors for fibrinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX) and collagen (GPIa/Iia) are not correlated with an increased risk for stroke. Stroke 1997;28:1392-5
   PubMed Web of Science ®Google Scholar
• Wagner KR, Giles WH, Johnson CJ, Platelet glycoprotein receptor IIIa polymorphism P1A2 and ischemic stroke risk: the Stroke prevention in young women study. Stroke 1998;29:581-5
   PubMed Web of Science ®Google Scholar
• Keating MT, Sanguinetti MC. Molecular genetic insights into cardiovascular disease. Science 1996;272:681-5
   PubMed Web of Science ®Google Scholar
• Zareba W, Moss AJ, Schwartz P, Influence of the genotype on the clinical course of the long-QT syndrome. N Engl J Med 1998;339:960-5
   PubMed Web of Science ®Google Scholar
• Schwartz PJ, Priori SG, Locati EH, Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na + channel blockage and to increases in heart rate: implications for gene specific therapy. Circulation 1995;92:3381-6
   PubMed Web of Science ®Google Scholar
• Donnan GA, Davis SM, Thrift A. The role of blood pressure lowering before and after stroke. Curr Opin Neurol 2003;16:81-6
   PubMedGoogle Scholar
• Nicolaou M, DeStefano AL, Gavras I, Genetic predisposition to stroke in relatives of hypertensives. Stroke 2000;31:487-92
   PubMedGoogle Scholar
• Lifton RP, Dluhy RG, Powers M, A chimaeric 1 beta-hydroxytase/aldosterone synthase gene causes glucocorticoid-remediable aldosterism and human hypertension. Nature 1992;355:262-5
   PubMed Web of Science ®Google Scholar
• Shimkets RA, Warnock DG, Bositis CM, Liddle's syndrome: heritable human hypertension causes by mutations in the beat-subunit of the epithelial sodium channel. Cell 1994;79:407-14
   PubMed Web of Science ®Google Scholar
• Bianchi G, Tripodi G, Casari G, Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci 1994;91:3999-4003
   PubMed Web of Science ®Google Scholar
• Hingorani AD, Jia H, Stevens PA, Renin-angiotensin system gene polymorphism influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995;13:1602-9
   PubMed Web of Science ®Google Scholar
• O'Donnell CJ, Lindpaintner K, Larson MG, Evidence for association and genetic linkage of the angiotensinconverting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 1998;97:1766-72
   PubMed Web of Science ®Google Scholar
• Agerholm-Larsen B, Tybjaerg-Hansen A, Frikke-Schmidt R, ACE gene polymorphism as a risk factor for ischemic cerebrovascular disease. Ann Intern Med 1997;127:346-55
   PubMed Web of Science ®Google Scholar
• Ansell BJ. Cholesterol, stroke risk, and stroke prevention. Curr Atheroscler Rep 2000;2:92-6
   PubMedGoogle Scholar
• Roses AD. Apolipoprotein E in neurology. Curt Opin Neurol 1996;9:265-70
   PubMedGoogle Scholar
• Pedro-Botet J, Senti M, Nogues X, Lipoprotein and apolipoprotein profile in men with ischemic stroke, Role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke 1992;23:1556-62
   PubMed Web of Science ®Google Scholar
• Nicoll JA, Burnett C, Love S, High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral Amyloid: angiopathy. Ann Neurol 1997;41:716-21
   PubMed Web of Science ®Google Scholar
• Greenberg SM, Rebeck GW, Vonsattel JP, Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 1995;38:254-9
   PubMed Web of Science ®Google Scholar
• Woo D, Sauerbeck LR, Kissela BM, Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a populations-based study. Stroke 2002; 33:1190-6
   PubMed Web of Science ®Google Scholar
• Jeng JS, Sacco RL, Kargman DE, Apolipoproteins and carotid artery atherosclerosis in an elderly multiethnic population: the Northern Manhattan stroke study. Atherosclerosis 2002;165:317-25
   PubMed Web of Science ®Google Scholar
• Sacco RL. Reducing the risk of stroke in diabetes: what have we learned that is new? Diabetes Obes Metab 2002;4 Suppl 1:S27-S34
   Google Scholar
• Awata T, Kurihara S, Kikuchi C, Evidence for an association between the class 1 subset of the insulin gene mini-satellite (IDDM 2 locus) and IDDM in the NIDDM. Diabetes 1997;46:1725-32
   PubMedGoogle Scholar
• Yamagata K, Oda N, Kaisaki PJ, Mutations in the hepatocyte nuclear factor-1 alpha gene in maturity onset diabetes of the young (MODY3). Nature 1996;384:455-8
   PubMed Web of Science ®Google Scholar
• Davies JL, Kawaguchi Y, Bennett ST, A genomewide search for human type 1 diabetes susceptibility genes. Nature 1994;371:130-6
   PubMed Web of Science ®Google Scholar
• Fava D, Gardner S, Pyke D, Evidence that the age oat diagnosis of IDDM is genetically determined. Diabetes Care 1998;21:925-9
   PubMedGoogle Scholar
• Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke r-tPA Stroke Study Group. N Engl J Med 1995;333(24):1581-7
   PubMed Web of Science ®Google Scholar
• Molina CA, Montaner J, Arenillas JF, Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke 2004;35(2):486-90
   PubMedGoogle Scholar
• Wardlaw JM, Warlow CP, Counsell C. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet 1997;350(9078):607-14
   PubMedGoogle Scholar
• Dubinsky R, Lai SM. Mortality of stroke patients treated with thrombolysis: analysis of nationwide inpatient sample. Neurology 2006;66(11):1742-4
   PubMedGoogle Scholar
• Sheehan JJ, Tsirka SE. Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review. Glia 2005;50(4):340-50
   PubMedGoogle Scholar
• Broderick J, Lu M, Jackson C, Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. Ann Neurol 2001;49(6):736-44
   PubMedGoogle Scholar
• Ladenvall P, Nilsson S, Jood K, Genetic variation at the human tissue-type plasminogen activator (tPA) locus: haplotypes and analysis of association to plasma levels of tPA. Eur J Hum Genet 2003;11(8):603-10
   PubMedGoogle Scholar
• Montaner J, Fernández-Cadenas I, Molina CA, Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene. Stroke 2003;34(12):2851-5
   PubMedGoogle Scholar
• Fernández-Cadenas I, Alvarez Sabín J, Molina CA, ApoE genotype influences on efficacy and safety of thrombolytic treatment for ischemic stroke. Neurologia 2006;21(4):176-80
   PubMedGoogle Scholar
• Fernández-Cadenas I, Molina CA, Alvarez-Sabín J, ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neurosci Lett 2006;398(3):167-71
   PubMedGoogle Scholar
• González-Conejero R, Fernández-Cadenas I, Iniesta JA, Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke 2006;37(9):2288-93
   PubMedGoogle Scholar
• Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M, Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. J Thromb Haemost 2007;5(9):1862-8
   PubMedGoogle Scholar
• Aithal GP, Day CP, Kesteven PJL, Association of the polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-19
   PubMed Web of Science ®Google Scholar
• Miners JO, Birkett DJ. Cytochrome P45029: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45:525-38
   PubMed Web of Science ®Google Scholar
• Rettie AE, Wienkers LC, Gonzales FJ, Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42
   PubMedGoogle Scholar
• Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics 1997;203-10
   PubMedGoogle Scholar
• Takahashi H, Kashima T, Nomoto S, Comparisons between in vitro metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 1998;8:365-73
   PubMedGoogle Scholar
• Taube J, Halsall D, Baglin T. Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000;96:1816-9
   PubMed Web of Science ®Google Scholar
• Ablin J, Cabili S, Eldor A, Warfarin therapy is feasible in CYP2C9*3 homozygous patients. Europ J of Inter Med 2004;15:22-7
   PubMedGoogle Scholar
• Rieder MJ, Reiner AP, Gage BF, Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352(22):2285-93
   PubMedGoogle Scholar
• Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
   PubMed Web of Science ®Google Scholar
• Fontana P, Dupont A, Gandrille S, Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequenze variations in healthy subjects. Circulation 2003;108:989-95
   PubMed Web of Science ®Google Scholar
• Fontana P, Gaussem P, Aiach M, P2Y12, H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation 2003;108:2971-3
   PubMed Web of Science ®Google Scholar
• Lordkipanidzè M, Pharand C, Palisaitis DA, Aspirin resistence: truth or dare. Pharmacology Therapeutics 2006;112:733-43
   PubMedGoogle Scholar
• Andrioli G, Minuz P, Solero P, Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa). Br J Haematol 2000;110:911-8
   PubMed Web of Science ®Google Scholar
• Szczeklik A, Undas A, Sanas M, Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol 2000;110:965-7
   PubMed Web of Science ®Google Scholar
• Undas A, Brummel K, Musial J, PlA2 polymorphism of beta-3 integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001;104:2666-72
   PubMed Web of Science ®Google Scholar
• Jefferson BK, Foster JH, McCarthy JJ, Aspirin resistance and a single gene. Am J Cardiol 2005;95:805-8
   PubMed Web of Science ®Google Scholar
• Hetherington SL, Singh RK, Lodwick D, Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vasc Biol 2005;25:252-7
   PubMed Web of Science ®Google Scholar
• Terres W, Weber K, Kupper W, Age, cardiovascular risk factors and coronary heart disease as determinant of platelet function in men: a multivariate approach. Thromb Res 1991;62(6):649-61
   PubMedGoogle Scholar
• Opper C, Clement C, Schwarz H, Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular disease, and after incubation with cholesterol. Atherosclerosis 1995;113(2):211-17
   PubMedGoogle Scholar
• Rosenson RS, Tangney CC. Antithrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279(20):1643-50
   PubMedGoogle Scholar
• Hamet P, Skuherska R, Pang SC, Abnormalities of platelet function in hypertension and diabetes. Hypertension 1985;7: II-135-42
   Google Scholar
• Kjeldsen SE, Rostrup M, Gjesdal K, The epinephrine-blood platelet connection with special reference to essential hypertension. Am Hearth J 1991;122:330-6
   PubMedGoogle Scholar
• Jimenez AH, Tofler GH, Chen X, Hemodynamic and hemostatic responses to morning and evening exertion in systemic hypertension and implications for triggering of acute cardiovascular disease. Am J Cardiol 1994;74:253-7
   PubMedGoogle Scholar
• Terres W, Becker P, Rosemberg A. Changes in cardiovascular risk profile during the cessation of smoking. Am J Med 1994;97(3):242-9
   PubMedGoogle Scholar
• Reunad SC, Beswick AD, Fehily AM, Alcohol and platelet aggregation: the Caerphilly prospective heart disease study. Am J Clin Nutr 1992;55(5):1012-17
   PubMedGoogle Scholar
• Mori TA, Beilin LJ, Burke V, Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 1997;17(2):279-86
   PubMedGoogle Scholar
• O'Donnel CJ, Larson MG, Feng D, Genetic and environmental contributions to platelet aggregation. The Framingham Heart Study. Circulation 2001;103:3051-6
   PubMed Web of Science ®Google Scholar
• Undas A, Sanak M, Musial J, Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 1999;353:982-3
   PubMed Web of Science ®Google Scholar
• Goodman T, Sharma P, Ferro A. The genetic of aspirin resistance. Int J Clin Pract 2007;61:826-34
   PubMed Web of Science ®Google Scholar
• Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008;66(2):222-32
   PubMedGoogle Scholar
• Feng D, Lindpaintner K, Larson MG, Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1999;19:1142-7
   PubMed Web of Science ®Google Scholar
• Goodall AH, Curzen N, Panesar M, Increased binding of fibrinogen to glycoprotein IIIa-proline33(HPA-1, PlA2, Zwb) positive platelets in patients with cardiovascular disease. Eur Heart J 1999;20:742-7
   PubMed Web of Science ®Google Scholar
• Michelson AD, Furman MI, Goldschmidt-Clermont P, Platelet GPIIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000;101:1013-8
   PubMed Web of Science ®Google Scholar
• Sirotkina OV, Khaspekova SG, Zabotina AM, Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists. Platelets 2007;18:506-14
   PubMed Web of Science ®Google Scholar
• Lasne D, Krenn M, Pingault V, Interdonor variability of platelet response to thrombin receptor activation: influence of PlA2 polymorphism. Br J Haematol 1997;99:801-7
   PubMed Web of Science ®Google Scholar
• Frey UH, Aral N, Muller N, Cooperative effect of GNB3 825C>T and GPIIIa Pl(A) polymorphisms in enhanced platelet aggregation. Thromb Res 2003;109:279-86
   PubMed Web of Science ®Google Scholar
• Cooke GE, Liu-Stratton Y, Ferketich AK, Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. JACC 2006;47:541-6
   Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, .; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360(4):363-75
   PubMedGoogle Scholar
• Paciaroni M, Agnelli G, Caso V, Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. Thromb Haemost 2005;3:1218-23
   Google Scholar
• Klungel OH, Stricker BH, Paes AH, Excess stroke among hypertensive men and women attributable to undertreatment of hypertension. Stroke 1999;30(7):1312-8
   PubMedGoogle Scholar
• European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25(5):457-507
   PubMedGoogle Scholar
• Hacke W, Donnan G, Fieschi C, Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS r-tPA stroke trials. Lancet. 2004;363(9411):768-74
   PubMed Web of Science ®Google Scholar
• Montaner J. Blood biomarkers to guide stroke thrombolysis. J Front Biosci 2009;1:200-8
   Google Scholar
• Antithrombotic Trialists' Collaboration: collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee: a randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39
   PubMed Web of Science ®Google Scholar
• Bhatt D, Fox K, Hacke W, Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17
   PubMed Web of Science ®Google Scholar
• van Rijn MJ, van Duijn CM, Slooter AJ. Impact of genetic testing on complex diseases. Eur J Epidemiol 2005;20(5):383-8
   PubMedGoogle Scholar
• Shen AY, Chen W, Yao JF, Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation. CNS Drugs. 2008;22(10):815-25
   PubMedGoogle Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, .; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51
   PubMed Web of Science ®Google Scholar